- Home
- Media centre
- Press release archive
Press release archive
[an error occurred while processing this directive] [an error occurred while processing this directive]
04 February 2010
GSK launches new specialist unit to research and develop medicines for rare diseases
04 February 2010
GSK announces appointment of Philippe Fauchet as President of GSK Japan
04 February 2010
Results announcement for the fourth quarter 2009
27 January 2010
Rotarix™ significantly reduced severe rotavirus gastroenteritis in African babies during their first year of life
22 January 2010
Arzerra (ofatumumab) receives positive opinion for conditional approval in Europe for refractory chronic lymphocytic leukaemia
20 January 2010
GSK announces ‘open innovation’ strategy to help deliver new and better medicines for people living in the world’s poorest countries
18 January 2010
GSK contributes to Haiti relief efforts
15 January 2010
GlaxoSmithKline update: Government orders for pandemic H1N1 vaccine
12 January 2010
GlaxoSmithKline update: Government orders for pandemic H1N1 vaccine
11 January 2010
GSK exercises option to progress development of ChemoCentryx’s Traficet-EN for the treatment of inflammatory bowel diseases
[an error occurred while processing this directive] [an error occurred while processing this directive]
18 December 2009
Revolade (eltrombopag) receives positive opinion in Europe for chronic immune thrombocytopenic purpura
16 December 2009
GlaxoSmithKline and NanoBio announce OTC licensing agreement for cold sore treatment
14 December 2009
GSK publishes speaking, consulting fees paid to US healthcare professionals
11 December 2009
GSK study showed targeted therapy combination achieved 14 month overall survival in patients with advanced breast cancer
11 December 2009
GSK and Intercell form strategic alliance to develop and commercialise innovative needle-free patch-based vaccines
10 December 2009
Pre-Budget Report response - GSK comments on ‘patent box’
09 December 2009
GSK initiates second pivotal Phase III trial for investigational cardiovascular medication Darapladib
01 December 2009
GSK Update: GSK’s Arepanrix™ H1N1 pandemic vaccine prequalified by the World Health Organization
01 December 2009
GSK completes extension of strategic collaboration with Aspen
30 November 2009
GlaxoSmithKline announced as Tier 3 Sponsor as London 2012 anti-doping plans confirmed
30 November 2009
Regulatory Update: GSK files Rotarix for prevention of rotavirus in Japan
24 November 2009
GlaxoSmithKline and Gilead announce agreement to commercialise Viread® for chronic hepatitis B in key Asian countries
23 November 2009
GSK Regulatory Update: Avodart
23 November 2009
Pandemic 2009 Influenza Update: Pandemrix™ data in children and adolescents from 3 to 17 years of age
16 November 2009
GSK and Nabi announce agreement for NicVAX®, a vaccine for nicotine addiction
10 November 2009
Pandemic 2009 Influenza Update: US FDA approves GSK’s pandemic H1N1 vaccine
10 November 2009
GSK signs agreement with the WHO to donate 50 million doses of pandemic H1N1 vaccine for distribution to developing countries
09 November 2009
Pandemic 2009 Influenza Update: Pandemrix™ data on co-administration with annual seasonal influenza vaccine (Fluarix®)
09 November 2009
GlaxoSmithKline and XenoPort announce extension of GSK1838262 (XP13512) FDA review date to 9 February, 2010
06 November 2009
World Health Organization Grants Prequalification for Global Use to GSK’s 10-Valent Synflorix™ Vaccine
03 November 2009
World’s largest malaria vaccine trial now underway in seven African countries
03 November 2009
ViiV Healthcare launches: A new specialist HIV company dedicated to delivering advances in HIV treatment and care
02 November 2009
Retigabine Regulatory Update
02 November 2009
GlaxoSmithKline and Human Genome Sciences announce positive results in second of two phase 3 trials of Benlysta in systemic lupus erythematosus
28 October 2009
Results announcement for the third quarter 2009
27 October 2009
Pandemic 2009 Influenza Update: Pandemrix™ data in an elderly population
27 October 2009
GlaxoSmithKline and Theravance commence Phase III Horizon programme to develop a next-generation treatment for COPD
26 October 2009
GSK and Genmab receive accelerated approval for Arzerra™
23 October 2009
Pandemic (H1N1) 2009 Influenza Update: Experience of GSK’s H1N1 adjuvanted vaccine, Pandemrix™, and preliminary paediatric results
19 October 2009
FDA approves GlaxoSmithKline’s Votrient™ for advanced renal cell cancer
16 October 2009
FDA approves Cervarix, GlaxoSmithKline’s cervical cancer vaccine
16 October 2009
GSK’s Cervarix® becomes the first cervical cancer vaccine to gain approval in Japan
13 October 2009
GlaxoSmithKline and Prosensa form alliance to fight Duchenne Muscular Dystrophy
13 October 2009
GSK partners with UK Government and Wellcome Trust to stimulate innovation through the creation of a world-class science park
12 October 2009
GSK’s Avodart® / tamsulosin combination showed benefits for men with prostate enlargement
08 October 2009
GlaxoSmithKline and U.S. Patent and Trademark Office file a motion to dismiss litigation over Final Regulations
06 October 2009
GSK expands presence in China through strategic cooperation to form a joint venture on paediatric vaccines
06 October 2009
GlaxoSmithKline update: Government orders for pandemic (H1N1) 2009 vaccine
05 October 2009
GlaxoSmithKline receives unanimous FDA Panel approval recommendation for Votrient™
01 October 2009
Avodart (dutasteride) regulatory update
30 September 2009
Pandemic (H1N1) 2009 Influenza Update: GSK’s H1N1 ‘Pandemrix’ vaccine receives European Commission Approval
29 September 2009
GlaxoSmithKline update on FDA review of Cervarix
29 September 2009
Fatality reported in UK HPV vaccine immunisation programme
28 September 2009
GSK and UPCH to launch Lucozade across China
28 September 2009
GSK provides update on regulatory filings for Zunrisa/Rezonic
25 September 2009
Pandemic (H1N1) 2009 Influenza Update: GSK’s H1N1 ‘Pandemrix’ vaccine receives positive opinion from European Regulators
14 September 2009
Pandemic (H1N1) 2009 Influenza Update: Initial results from first clinical trial of GSK’s H1N1 adjuvanted vaccine
09 September 2009
FDA Advisory Committee makes favorable recommendation for Cervarix, GlaxoSmithKline’s candidate cervical cancer vaccine
17 August 2009
GlaxoSmithKline and Genmab announce results from a study of Arzerra in rituximab refractory follicular NHL
17 August 2009
GSK and Brazil’s Fiocruz form partnership for new R&D effort and increased vaccine access
14 August 2009
Pandemic (H1N1) 2009 influenza update
04 August 2009
GlaxoSmithKline update: Government orders for pandemic (H1N1) 2009 vaccine
29 July 2009
GlaxoSmithKline and Genmab announce top-line results for ofatumumab in rheumatoid arthritis
29 July 2009
Regulatory update: mepolizumab for the treatment of hypereosinophilic syndrome (HES)
27 July 2009
Amgen to collaborate with GSK to commercialize denosumab in Europe for postmenopausal osteoporosis (PMO)
22 July 2009
GlaxoSmithKline completes acquisition of Stiefel
22 July 2009
Results announcement for the second quarter 2009
22 July 2009
Pandemic (H1N1) 2009 Influenza Update
21 July 2009
GSK and Enigma Diagnostics announce commercial partnership to develop point-of-care influenza diagnostics
09 July 2009
WHO grants prequalification to Cervarix®: GSK’s vaccine to help combat cervical cancer in developing nations
08 July 2009
Alnylam joins GSK in donating intellectual property to patent pool for neglected tropical diseases
07 July 2009
Landmark study for GSK’s cervical cancer vaccine published in The Lancet
02 July 2009
GSK further extends its product portfolio in the Middle East and North Africa
26 June 2009
Seretide: Irish patent litigation update
23 June 2009
GSK and Chroma Therapeutics form alliance to develop novel macrophage-targeted drugs
23 June 2009
Regulatory update for REZONIC™ (casopitant mesylate)
16 June 2009
FDA extends review of Arzerra™ (ofatumumab)
15 June 2009
GSK announces a strategic alliance with Dr. Reddy’s to further accelerate sales growth in emerging markets
12 June 2009
GlaxoSmithKline update: A (H1N1) influenza
09 June 2009
GSK and Shenzhen Neptunus create new alliance to develop and manufacture influenza vaccines in China
05 June 2009
World Health Organization grants Global Prequalification to GSK’s Rotarix™ vaccine
05 June 2009
Positive results with Revolade™ and Arzerra™ for difficult-to-treat blood disorders
02 June 2009
GSK and Concert Pharmaceuticals form alliance to develop novel deuterium-modified drugs
01 June 2009
GSK’s Pazopanib significantly delayed tumor progression in patients with advanced kidney cancer
29 May 2009
FDA advisory panel makes favorable recommendation for ARZERRA (ofatumumab)
15 May 2009
GlaxoSmithKline update: A (H1N1) influenza vaccine development
12 May 2009
GSK extends strategic collaboration with Aspen
08 May 2009
Community healthcare charities receive £300,000 from GlaxoSmithKline in recognition of their work
06 May 2009
GlaxoSmithKline to divest US rights for Wellbutrin XL® to Biovail for $510 million
01 May 2009
GlaxoSmithKline update: influenza A (H1N1)
27 April 2009
Large, long-term study shows dutasteride reduced prostate cancer risk in men at increased risk of the disease
27 April 2009
Emergence of a new H1N1 influenza A strain (swine influenza)
20 April 2009
GlaxoSmithKline launches alli® (orlistat 60 mg)
20 April 2009
GlaxoSmithKline and Stiefel to create new world-leading specialist dermatology business
16 April 2009
GlaxoSmithKline and Pfizer announce innovative agreement to create a new world-leading, specialist HIV company
01 April 2009
GSK submits Tyverb®/Tykerb® (lapatinib) for first-line treatment of metastatic breast cancer in Europe, US
31 March 2009
Synflorix™, GlaxoSmithKline’s pneumococcal vaccine, receives European authorisation
30 March 2009
Cervarix® U.S. regulatory update
24 March 2009
GSK publishes 2008 Corporate Responsibility Report
19 March 2009
GlaxoSmithKline announces sale of shares in Quest Diagnostics Inc.
05 March 2009
NICE refuses funding for advanced breast cancer treatment, Tyverb® (lapatinib)
04 March 2009
GlaxoSmithKline submits European marketing authorisation application for Pazopanib in advanced kidney cancer
17 February 2009
GSK initiates phase III programme for novel type 2 diabetes medication, Syncria® (albiglutide)
06 February 2009
GlaxoSmithKline and Idenix Pharmaceuticals sign worldwide license agreement for IDX899, a novel NNRTI for the treatment of HIV
05 February 2009
GlaxoSmithKline and Genmab seek European marketing authorisation of Arzerra™ (ofatumumab) in advanced stage blood cancer
05 February 2009
Results announcement for the fourth quarter 2008
04 February 2009
GSK and Theravance announce positive phase 2b results for once-daily fluticasone furoate in the treatment of asthma
02 February 2009
GlaxoSmithKline plc, announces board changes
30 January 2009
GlaxoSmithKline and Genmab submit Arzerra (Ofatumumab) application to FDA for the treatment of advanced stage blood cancer
30 January 2009
Deirdre Connelly to join GSK as President, North American Pharmaceuticals
29 January 2009
GSK announces charges for legal matters
29 January 2009
The UK Government signs influenza pandemic contract with GlaxoSmithKline for Relenza®
23 January 2009
GSK to drive growth in emerging markets with acquisition of UCB products
22 January 2009
GSK’s paediatric pneumococcal candidate vaccine Synflorix™ receives positive opinion in Europe
21 January 2009
GlaxoSmithKline receives European Commission approval to market alli® (orlistat 60mg)
09 January 2009
GSK and Xenoport resubmit new drug application for Solzira™ in restless legs syndrome
07 January 2009
GlaxoSmithKline successfully completes tender offer for shares of Genelabs Technologies, Inc.
[an error occurred while processing this directive] [an error occurred while processing this directive]
23 December 2008
Cytokinetics retains development and commercialization rights to ispinesib and SB-743921
23 December 2008
GlaxoSmithKline and Archemix form strategic alliance to develop aptamers to treat inflammatory diseases
22 December 2008
GlaxoSmithKline to cease providing corporate political contributions
22 December 2008
GSK and Theravance announce positive phase 2b results for LABA `444 in the treatment of COPD in the Horizon Development Programme
22 December 2008
GSK to acquire BMS Pakistan
19 December 2008
GSK files for European Marketing Authorisation of Duodart® for benign prostatic hyperplasia
18 December 2008
GSK initiates phase lll programme for novel cardiovascular medication, darapladib
17 December 2008
GlaxoSmithKline and Dynavax announce worldwide strategic alliance
12 December 2008
'Green' canal water helps fuel 21st century business
11 December 2008
GlaxoSmithKline statement on FDA Advisory Committee vote on use of asthma medicines containing long-acting beta-agonists
08 December 2008
Arzerra™ (ofatumumab) demonstrates high response rates in patients with fludarabine refractory chronic lymphocytic leukemia (CLL)
08 December 2008
GlaxoSmithKline extends tender offer for Genelabs Technologies, Inc.
08 December 2008
Two new studies in the New England Journal of Medicine show malaria vaccine candidate advancing in Africa
05 December 2008
GSK analysis shows Seretide/Advair is a well tolerated and effective medicine for controlling asthma
04 December 2008
GlaxoSmithKline and The Carter Center reaffirm commitment to global public health with expansion of LF program
03 December 2008
GSK announces waiver of a condition to the tender offer for Genelabs Technologies
02 December 2008
GSK and Theravance announce positive phase 2b results for LABA, `444 in the Horizon Asthma Development programme
21 November 2008
GSK and Neptunus sign cooperation agreement to form joint venture for the co-development of flu vaccines in China, Hong Kong and Macau
20 November 2008
FDA approves Promacta® (eltrombopag), the first oral medication to increase platelet production for people with serious blood disorder
20 November 2008
GSK to strengthen OTC analgesic business with acquisition of Alvedon
20 November 2008
Cervarix, GSK’s cervical cancer vaccine, wins tender for Dutch national immunisation programme
12 November 2008
GSK commences tender offer to acquire Genelabs Technologies, Inc.
11 November 2008
GSK proposes to close Dartford manufacturing site in the UK by 2013
10 November 2008
GSK and Xenoport announce plans to withdraw and resubmit new drug application requesting approval of Solzira™ for restless legs syndrome
29 October 2008
GlaxoSmithKline to acquire Genelabs Technologies to increase focus on novel small molecule therapies for Hepatitis C
23 October 2008
GlaxoSmithKline and AFFiRiS sign an exclusive licence and option agreement for therapeutic Alzheimer’s disease candidate vaccines
22 October 2008
Results announcement for the third quarter 2008
21 October 2008
GlaxoSmithKline to acquire the leading dry mouth brand, Biotene
15 October 2008
GSK’s Emerging Markets strategy advances with acquisition in Egypt
08 October 2008
LF Elimination programme treats over half billion people and protects millions more from debilitating disease
19 September 2008
GSK update on FDA review of Promacta® (eltrombopag)
16 September 2008
New data for GlaxoSmithKline’s pre-pandemic H5N1 influenza vaccine, Prepandrix™, show administration flexibility for pandemic planning
16 September 2008
GSK and Xenoport announce submission of new drug application requesting FDA approval of Solzira™ for Restless Legs Syndrome
15 September 2008
Pazopanib shows encouraging activity in several tumour types, including soft tissue sarcoma and ovarian cancer
14 September 2008
Tyverb® demonstrates encouraging results in Phase II study in advanced head and neck cancer
12 September 2008
ESMO 2008 - GlaxoSmithKline to present encouraging new data supporting late stage development programme
10 September 2008
GlaxoSmithKline and Cellzome announce major strategic alliance
09 September 2008
Ellen Strahlman appointed Chief Medical Officer at GlaxoSmithKline
08 September 2008
GlaxoSmithKline plc – Directorate change
02 September 2008
GlaxoSmithKline’s darapladib modifies coronary plaque composition and lowers Lp-PLA2 activity, a biomarker predictive of heart attack risk
28 August 2008
GlaxoSmithKline and Valeant Pharmaceuticals announce worldwide collaboration agreement for retigabine
23 July 2008
Results announcement for the second quarter 2008
23 July 2008
GSK sets out new strategic priorities
23 July 2008
GSK enters transformational agreement with Aspen to drive growth in emerging markets
22 July 2008
Dan Troy appointed as Senior Vice President and General Counsel for GlaxoSmithKline
21 July 2008
GlaxoSmithKline teams up with academia to develop new medicines of value
21 July 2008
GlaxoSmithKline reaches settlement agreement with Biota
07 July 2008
GSK receives BITC CommunityMark for global community programmes
01 July 2008
GlaxoSmithKline to appeal judgment in Alabama Medicaid pricing suit
30 June 2008
GSK and Aspen enter product divestment agreement
30 June 2008
GlaxoSmithKline responds to FDA on Cervarix® and plans to submit final study data for approval
18 June 2008
Cervarix™, GSK’s cervical cancer vaccine, wins tender for UK national immunisation programme
18 June 2008
GlaxoSmithKline responds to Government announcement on the PPRS
06 June 2008
GlaxoSmithKline acquires Sirtris Pharmaceuticals, Inc., a world leader in sirtuin research and development
02 June 2008
GlaxoSmithKline successfully completes tender offer for shares of Sirtris Pharmaceuticals
22 May 2008
GlaxoSmithKline announces $500,000 in fellowships at Stanford Graduate School of Business
21 May 2008
GlaxoSmithKline plc - results of AGM
19 May 2008
First pre-pandemic vaccine approved to help protect against pandemic influenza
15 May 2008
The battle against obesity: European experts and pharmacists call for an increased role for pharmacy
12 May 2008
Lapatinib (Tykerb/Tyverb) to be investigated in landmark early breast cancer trial
02 May 2008
GlaxoSmithKline commences tender offer to acquire Sirtris Pharmaceuticals
30 April 2008
FDA approves Advair 250/50 for reduction of exacerbations in patients with COPD
30 April 2008
GSK announces changes to Corporate Executive Team
29 April 2008
GlaxoSmithKline awards £300,000 to community health charities in recognition of their work
25 April 2008
GSK receives positive opinion for conditional approval of new oral breast cancer treatment, Tyverb (lapatinib)
23 April 2008
Results announcement for the first quarter 2008
22 April 2008
GlaxoSmithKline to acquire Sirtris Pharmaceuticals, a world leader in 'Sirtuin' research and development
22 April 2008
GlaxoSmithKline reports further progress of oncology portfolio
15 April 2008
Treximet (sumatriptan and naproxen sodium) tablets approved by FDA for acute treatment of migraine
08 April 2008
GlaxoSmithKline confirms receipt of FDA letter on regulatory reporting
02 April 2008
GlaxoSmithKline statement - Lancet publication of D:A:D data
19 March 2008
GSK charitable support valued at GBP282 million in 2007
18 March 2008
Tyverb (lapatinib) European regulatory update
06 March 2008
GSK statement on MHRA investigation
03 March 2008
FDA grants Priority Review For Promacta / Revolade (Eltrombopag)
29 February 2008
Update on GSK's malaria treatments: Dacart and Lapdap
28 February 2008
XenoPort and GlaxoSmithKline report positive top-line results of final pivotal trial of XP13512/GSK1838262 for restless legs syndrome
26 February 2008
GlaxoSmithKline statement: Public Library of Science Medicine article on antidepressant medicines
26 February 2008
GlaxoSmithKline and Theravance announce expansion of the Horizon programme with start of large Phase 2B study of LABA in COPD patients
21 February 2008
GSK's Volibris (ambrisentan) receives EMEA positive opinion for approval to treat class II and II pulmonary arterial hypertension (PAH)
19 February 2008
New price reductions for GSK antiretrovirals in the world's poorest countries
08 February 2008
FDA extends review of NDA for Entereg® (alvimopan)
07 February 2008
Full-year results announcement 2007
06 February 2008
GlaxoSmithKline responds to findings in ACCORD study
04 February 2008
GlaxoSmithKline and Amira Pharmaceuticals enter global agreement for FLAP inhibitor programme
31 January 2008
GlaxoSmithKline files pneumococcal paediatric vaccine in the EU
28 January 2008
GlaxoSmithKline welcomes European guidance that stockpiling more than one antiviral would be useful in preparing for a flu pandemic
28 January 2008
GlaxoSmithKline and Synta announce elesclomol granted US orphan drug designation by the FDA
24 January 2008
GSK appoints Lon Cardon to focus genetics on new disease targets
24 January 2008
GSK and MRC to identify new therapeutic targets and biomarkers from genetic association studies
24 January 2008
GlaxoSmithKline and TB Alliance renew tuberculosis drug discovery programme
24 January 2008
GlaxoSmithKline and Medicines For Malaria Venture announce new collaboration to investigate novel antimalarial compounds
24 January 2008
GlaxoSmithKline to revise Avandia® (rosiglitazone maleate) label in Europe following assessment by CHMP
15 January 2008
New allergic rhinitis treatment Avamys™ approved in Europe
15 January 2008
GlaxoSmithKline and XenoPort report positive top-line results of second phase 3 restless legs syndrome trial for XP13512/GSK1838262
03 January 2008
GlaxoSmithKline and Theravance announce start of large Phase 2B ICS and LABA studies for asthma in the Horizon programme
[an error occurred while processing this directive] [an error occurred while processing this directive]
20 December 2007
GlaxoSmithKline files for FDA approval of Promacta/Revolade (eltrombopag) to be the first oral platelet growth factor for rare blood disorder
19 December 2007
GlaxoSmithKline and Santaris Pharma enter global R&D alliance to discover, develop and commercialise RNA antagonists as novel antivirals
19 December 2007
GlaxoSmithKline completes acquisition of Reliant Pharmaceuticals
17 December 2007
GlaxoSmithKline receives FDA ‘complete response’ letter for cervical cancer vaccine
16 December 2007
GlaxoSmithKline announces data on Tykerb® (lapatinib) plus capecitabine for the treatment of HER2-positive breast cancer brain metastases
13 December 2007
GlaxoSmithKline presents innovative neuroscience pipeline
11 December 2007
GlaxoSmithKline responds to JAMA article on the ICES thiazolidinediones and cardiovascular outcomes in older patients with diabetes
10 December 2007
GlaxoSmithKline receives decision from US FDA on Requip® XL™
10 December 2007
Long-term safety and efficacy data on Promacta™ (eltrombopag) presented at American Society of Hematology Annual Meeting
10 December 2007
GlaxoSmithKline and OncoMed Pharmaceuticals form strategic alliance to develop cancer stem cell antibody therapeutics
10 December 2007
GlaxoSmithKline and Galapagos enter strategic alliance to develop novel antibacterials and antivirals
07 December 2007
GlaxoSmithKline announces appointments to the Board of Directors
06 December 2007
GSK’s continued commitment to fighting HIV/AIDS results in approval of new formulations of three medicines for the treatment of children
03 December 2007
GSK response to Nature Medicine article on rosiglitazone and bone in mice
28 November 2007
GSK statement on US Food and Drug Administration Pediatric Advisory Committee recommendations regarding salmeterol
26 November 2007
GlaxoSmithKline obtains exclusive US OTC marketing rights to Mevacor® (lovastatin) from Merck & Co., Inc.
21 November 2007
GlaxoSmithKline to acquire Reliant Pharmaceuticals
20 November 2007
GlaxoSmithKline and Genmab initiate ofatumumab rheumatoid arthritis Phase III programme
15 November 2007
GSK and the European Foundation for the Study of Diabetes (EFSD) commit €1 million to diabetes research in Europe
14 November 2007
GlaxoSmithKline revises US labeling for Avandia
07 November 2007
Prometheus to acquire Lotronex® from GlaxoSmithKline
05 November 2007
New innovation grants boost malaria advocacy efforts in Africa
02 November 2007
Fabre Kramer Pharmaceuticals receives decision from FDA on gepirone ER for major depressive disorder
24 October 2007
Results announcement for the third quarter 2007
23 October 2007
GlaxoSmithKline and Tolerx form worldwide collaboration for development and commercialisation of novel medication
19 October 2007
New allergic rhinitis treatment Avamys™ receives positive opinion in Europe
18 October 2007
European Medicine Agency (EMEA) confirms positive Avandia benefit risk assessment
17 October 2007
New Lancet study: Malaria vaccine candidate has promising safety, tolerability profile in infants
15 October 2007
GSK receives approval for Hycamtin® (topotecan) capsules for the treatment of relapsed small cell lung cancer
10 October 2007
GlaxoSmithKline and Synta Pharmaceuticals announce development and commercialisation collaboration for STA-4783 in oncology
08 October 2007
GlaxoSmithKline appoints Andrew Witty CEO designate
08 October 2007
GlaxoSmithKline and Anacor Pharmaceuticals form alliance to develop systemic antivirals and antibiotics based on boron chemistry
04 October 2007
GSK seeks prequalification for Cervarix™ from the World Health Organization after obtaining marketing approval in Europe
02 October 2007
GSK applies for licence to market OTC weight loss product In Europe
28 September 2007
GSK submits Cervarix licence application to Japan's health authorities
28 September 2007
GlaxoSmithKline plc announces change to the Board of Directors
27 September 2007
GlaxoSmithKline helps form the Serious Adverse Events Consortium
25 September 2007
GlaxoSmithKline named to Working Mother "100 Best Companies" list
24 September 2007
Cervarix, GSK's cervical cancer vaccine, approved In Europe
21 September 2007
GSK receives decision from FDA on Lamictal®XR™ Extended-Release Tablets
11 September 2007
GlaxoSmithKline and Sepracor Inc. announce international alliance for commercialisation of Lunivia
11 September 2007
GlaxoSmithKline responds to JAMA articles
04 September 2007
Study shows combination therapy incorporating Avodart® and tamsulosin provides continuous symptom improvement over two years
03 September 2007
GlaxoSmithKline's Arixtra® receives European authorisation for the treatment of acute coronary syndromes
28 August 2007
FDA accepts for review complete response to approvable letter for Entereg® (alvimopan) for POI
16 August 2007
GlaxoSmithKline signs contract for its pandemic flu vaccine with UK Government
14 August 2007
GlaxoSmithKline's application for Rotarix® is accepted for review by the FDA
14 August 2007
GlaxoSmithKline updates prescribing information for Avandia in the US
08 August 2007
GSK gives consent under Canada's Access to Medicines Regime for generic version of HIV/AIDS medicine for use in Rwanda
08 August 2007
GSK receives decision from FDA on Advair 500/50 for COPD
03 August 2007
GlaxoSmithKline receives new HHS order for H5N1 bulk antigen
02 August 2007
FDA issues second approvable letter for Trexima™
02 August 2007
GSK comments on UK Government announcement to renegotiate current Pharmaceutical Pricing and Regulation Scheme agreement
30 July 2007
GlaxoSmithKline presents Avandia data to FDA
30 July 2007
Pharmetrics epidemiology study
30 July 2007
FDA Advisory Panel votes 22 to 1 for Avandia® to remain available to patients in the US
27 July 2007
GlaxoSmithKline statement in diabetes care study thiazolidinediones and heart failure: a teleo-analysis [1]
27 July 2007
GlaxoSmithKline and Targacept form alliance in therapeutics for CNS-related disorders
25 July 2007
New head-to-head study comparing Lexiva® and atazanavir show similar efficacy and lipid changes
25 July 2007
Results announcement for the second quarter 2007
17 July 2007
GSK responds to online review of rosiglitazone by The Cochrane Collaboration
09 July 2007
GSK receives extended licence indication for Seretide in Europe following submission of TORCH data for COPD
18 June 2007
GlaxoSmithKline expects to launch up to five major new medicines for oncology in next three years
13 June 2007
GlaxoSmithKline to make unprecedented vaccine donation to WHO pandemic flu stockpile
13 June 2007
GlaxoSmithKline's application for DTaP-IPV vaccine is accepted for review by the FDA
12 June 2007
alli™ - the OTC weight loss product - on shelves nationwide in the US later this week
11 June 2007
GlaxoSmithKline and Adolor update alvimopan (Entereg/Entrareg) development programme
06 June 2007
Newly published data from large study support cardiovascular safety of Avandia (rosiglitazone maleate)
06 June 2007
Statement of Moncef Slaoui, PhD, Chairman Research & Development, GlaxoSmithKline
05 June 2007
GlaxoSmithKline response to New England Journal of Medicine editorials
04 June 2007
Eight-year long-term data demonstrate prolonged overall survival and length of disease remission with BEXXAR
01 June 2007
GlaxoSmithKline announces Altargo approved in Europe for treatment of Impetigo and other skin infections
01 June 2007
GlaxoSmithKline honours cancer research pioneer Gianni Bonadonna with new ASCO award and fellowship
30 May 2007
Data affirms Avandia (rosiglitazone maleate) cardiovascular safety profile
24 May 2007
GlaxoSmithKline launches Chinese R&D centre with appointment of head in Shanghai
23 May 2007
GlaxoSmithKline announces Swiss approval of Tyverb®, a new oral treatment for advanced breast cancer
23 May 2007
GlaxoSmithKline plc - results of AGM
22 May 2007
alli™ debuts through the alli Experience
21 May 2007
Cervarix™ is approved in Australia for females 10-45 years old
21 May 2007
GlaxoSmithKline responds to NEJM article on Avandia
21 May 2007
GlaxoSmithKline strongly defends its record on Avandia
08 May 2007
Fabre-Kramer refiles gepirone ER with the FDA for the treatment of major depressive disorder
02 May 2007
Trexima™ (sumatriptan/naproxen sodium) demonstrated efficacy across multiple migraine attacks
01 May 2007
New data shows once a day Lamictal® XR™ is effective in treating patients with partial seizures
30 April 2007
GlaxoSmithKline and Wellcome Trust announce partnership to target drug-resistant hospital infections
25 April 2007
Results announcement for the first quarter 2007
18 April 2007
GlaxoSmithKline receives Japanese approval for two major new product opportunities: Seretide/Advair and Arixtra
18 April 2007
Community health charities receive £265,000 in recognition of their work from GlaxoSmithKline
12 April 2007
GSK initiates repeat dosing study of its novel oral platelet growth factor, eltrombopag, in ITP
12 April 2007
GSK announces FDA approval of Altabax (retapamulin ointment), 1%
09 April 2007
GSK and Adolor announce preliminary results from phase 3 Safety study of Alvimopan (Entereg/Entrareg)
03 April 2007
Trexima (sumatriptan/naproxen sodium) superior efficacy data published in JAMA
02 April 2007
GlaxoSmithKline KK seeks approval in Japan for lapatinib, a new treatment for breast cancer
02 April 2007
FDA approves accelerated dosing schedule for GlaxoSmithKline's Twinrix
30 March 2007
GlaxoSmithKline files meningococcal conjugate vaccine
29 March 2007
GlaxoSmithKline submits biologics license application to US Food and Drug Administration for Cervarix
29 March 2007
GlaxoSmithKline appoints Zhi Hong to head infectious-diseases research centre
26 March 2007
New study indicates nicotine patches may be safe for helping patients with coronary artery disease to quit smoking
22 March 2007
GSK announces nationwide availability of once-a-day Coreg CR for the treatment of three key cardiovascular conditions
20 March 2007
FiberChoice plus multivitamins issues allergy alert
09 March 2007
New JACC analysis details cardiovascular protective benefits of carvedilol in heart failure patients
05 March 2007
New studies indicate GSK's pre-pandemic influenza vaccine can protect against different strains of H5N1
01 March 2007
Study published in New England Journal of Medicine: Vaccine 95.5% effective against neglected hepatitis E
27 February 2007
New data show fluticasone furoate nasal spray effectively treated nasal symptoms of allergic rhinitis
26 February 2007
GSK initiates first global Phase III study of Tykerb (lapatinib) in head and neck cancer
21 February 2007
Landmark study shows important benefits of Seretide treatment for patients with fatal lung disease, COPD
20 February 2007
GlaxoSmithKline acquires exclusive rights to over-the-counter orlistat for markets outside the US from Roche Group
20 February 2007
OFT market study into the Pharmaceutical Price Regulation Scheme
16 February 2007
GlaxoSmithKline successfully completes tender offer for shares of Praecis Pharmaceuticals
16 February 2007
GlaxoSmithKline Diseases of the Developing World ad campaign receives industry award
13 February 2007
WHO awards prequalification status to GSK rotavirus vaccine
13 February 2007
GlaxoSmithKline and Human Genome Sciences announce initiation of Phase 3 clinical trial of Lymphostat-B in systemic lupus erythematosus
13 February 2007
GlaxoSmithKline offers new tools to help patients get free medicines
12 February 2007
GlaxoSmithKline plc announces change to the Board of Directors
09 February 2007
GlaxoSmithKline commends $1.5 billion advance market commitment for pneumococcal vaccines
08 February 2007
Full-year results announcement 2006
08 February 2007
GlaxoSmithKline and XenoPort announce agreement on late-stage compound for RLS and neuropathic pain
08 February 2007
GlaxoSmithKline and Fabre-Kramer Pharmaceuticals enter global agreement for new treatment of major depressive disorder
07 February 2007
FDA approves alli (orlistat 60 mg capsules) over-the-counter
07 February 2007
GlaxoSmithKline accepts shares in tender offer for shares of Praecis Pharmaceuticals and commences subsequent offering period
02 February 2007
GlaxoSmithKline receives approvable letter for new indications for Arixtra (fondaparinux sodium) injection
02 February 2007
Valtrex (valacyclovir) - US patent litigation update
29 January 2007
GlaxoSmithKline statement - BBC Panorama - 29 January 2007
29 January 2007
GlaxoSmithKline files its new pre-pandemic influenza vaccine in Europe
18 January 2007
GlaxoSmithKline initiates head-to-head study of cervical cancer vaccines
16 January 2007
GlaxoSmithKline receives first European approval for Wellbutrin XR
09 January 2007
GlaxoSmithKline commences tender offer to acquire Praecis Pharmaceuticals
Back to top
